STAA

STAAR Surgical Co. 10-Q Summary: Quarter Ended June 28, 2024

Business Context and Reporting Period

STAAR Surgical Co. (STAA) is a Delaware corporation specializing in the design, development, and sale of implantable lenses for the eye, primarily the implantable Collamer lens (ICL) for refractive surgery. The company operates as a single segment and manufactures in the United States while selling globally. This report covers the quarterly period ended June 28, 2024, and the six-month period ended June 28, 2024.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. Debt consists primarily of finance lease obligations; the company has no long-term finance lease obligations as of June 28, 2024.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 7.3% year-over-year (YoY) for the quarter and 6.3% for the six-month period. This was driven by a 6.7% increase in ICL sales for the quarter, with unit volume up 3%.
• Margin Expansion: Gross margin improved to 79.2% (Q2) and 79.1% (YTD) compared to 76.6% and 77.4% in the prior year periods. Management attributes this to changes in reserves related to cataract IOLs recognized in the prior year.
• Expense Trends:
  • G&A: Increased 30.6% YoY (Q2) due to higher bonuses, stock-based compensation, and facility costs.
  • Selling & Marketing: Decreased 10.7% YoY (Q2) due to reduced advertising and promotional activities.
  • R&D: Increased 19.6% YoY (Q2) driven by salary-related expenses and stock-based compensation.
• Foreign Currency Impact: Unfavorable foreign currency fluctuations reduced net sales by approximately $1.4 million for the quarter and $2.3 million for the six-month period.
• Other Income/Expense: Net other expense increased significantly due to higher foreign exchange losses ($3.0 million loss in Q2 vs. $1.9 million in prior year Q2).

Outlook, Risks, and Contingencies

• Product Strategy: The company has phased out sales of cataract intraocular lenses (IOLs) and related injectors, focusing exclusively on the ICL refractive surgery business. No cataract IOL sales are expected in fiscal 2024.
• Geographic Concentration: China remains a critical market, accounting for 64% of net sales in Q2 2024 and 70% of trade receivables. Japan accounted for approximately 10% of sales.
• Liquidity: The company maintains a strong liquidity position with $192.8 million in cash and cash equivalents and $42.7 million in investments available for sale. Management believes these resources are sufficient for at least the next 12 months.
• Capital Expenditures: Significant investment in property, plant, and equipment occurred, with $11.4 million spent in the first six months of 2024. Additionally, $8.1 million in cloud-based software implementation costs were capitalized but not yet placed in service.
• Risks: Key risks include foreign currency volatility, reliance on China distributors, and the impact of global macroeconomic factors on elective surgical procedures.

Investor Verification Checklist

• China Exposure: Verify the stability of the 64% revenue concentration in China and the 70% concentration of trade receivables in that region.
• Expense Run Rate: Assess the sustainability of the 30% increase in G&A expenses and whether this is a one-time step-up or a new baseline.
• Foreign Exchange Sensitivity: Monitor the impact of currency fluctuations, which negatively impacted sales by over $2 million in the first half of the year.
• Capital Deployment: Review the timeline for the $8.1 million in capitalized cloud software costs to be placed in service (expected Q1 2025) and the return on the $11.4 million in recent capital expenditures.
• Stock-Based Compensation: Note the significant portion of expenses attributed to stock-based compensation ($9.0 million in Q2), which impacts non-GAAP profitability metrics.